EU devices regulation: steady moves forward or kneejerk reactions?
This article was originally published in Clinica
Should there be a major failure by a notified body in the next couple of years, it will call into question the entire medical device regulatory system. And this will accelerate major changes in the regulations as we know them today, writes Amanda Maxwell. That was view of Mika Reinkainen, managing director of the newly-established consultancy, Abnovo, at the regulatory sessions of the Medtec UK 2008 conference held in at the NEC, Birmingham, on February 13-14.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.